{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["adjunctive immunotherapy", "cancer", "natural products", "tumor microenvironment"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37570775", "DateCompleted": {"Year": "2023", "Month": "08", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "08", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "08", "Day": "01"}], "Language": ["eng"], "ELocationID": ["5804", "10.3390/molecules28155804"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "15", "PubDate": {"Year": "2023", "Month": "Aug", "Day": "01"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.", "Abstract": {"AbstractText": ["Triple-negative breast cancer (TNBC) is an invasive and persistent subtype of breast cancer that is likely to be resistant to conventional treatments. The rise in immunotherapy has created new modalities to treat cancer, but due to high costs and unreliable efficacy, adjunctive and complementary treatments have sparked interest in enhancing the efficacy of currently available treatments. Natural products, which are bioactive compounds derived from natural sources, have historically been used to treat or ameliorate inflammatory diseases and symptoms. As TNBC patients have shown little to no response to immunotherapy, the potential of natural products as candidates for adjuvant immunotherapy is being explored, as well as their immunomodulatory effects on cancer. Due to the complexity of TNBC and the ever-changing tumor microenvironment, there are challenges in determining the feasibility of using natural products to enhance the efficacy or counteract the toxicity of conventional treatments. In view of technological advances in molecular docking, pharmaceutical networking, and new drug delivery systems, natural products show promise as potential candidates in adjunctive therapy. In this article, we summarize the mechanisms of action of selected natural-product-based bioactive compounds and analyze their roles and applications in combination treatments and immune regulation."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Kan", "ForeName": "Lea Ling-Yu", "Initials": "LL"}, {"Identifier": ["0000-0001-5505-1065"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Chan", "ForeName": "Ben Chung-Lap", "Initials": "BC"}, {"Identifier": ["0000-0002-0195-4688"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Leung", "ForeName": "Ping-Chung", "Initials": "PC"}, {"Identifier": ["0000-0002-5637-8331"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, China."}, {"Identifier": [], "Affiliation": "Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Wong", "ForeName": "Chun-Kwok", "Initials": "CK"}], "GrantList": [{"GrantID": "00000", "Agency": "Innovation and Technology Commission", "Country": ""}, {"GrantID": "00000", "Agency": "Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, CUHK, Hong Kong", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pathology"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Immunotherapy"}, {"QualifierName": [], "DescriptorName": "Tumor Microenvironment"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Arnold M., Morgan E., Rumgaym H., Mafra A., Singh D., Laversanne M., Vignat J., Gralow J.R., Cardoso F., Siesling S., et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. doi: 10.1016/j.breast.2022.08.010.", "ArticleIdList": ["10.1016/j.breast.2022.08.010", "PMC9465273", "36084384"]}, {"Citation": "Giaquinto A.N., Sung H., Miller K.D., Kramer J.L., Newman L.A., Minihan A., Jemal A., Siegel R.L. Breast Cancer Statistics, 2022. CA Cancer J. Clin. 2022;72:524\u2013541. doi: 10.3322/caac.21754.", "ArticleIdList": ["10.3322/caac.21754", "36190501"]}, {"Citation": "Claus E.B., Schildkraut J.M., Thompson W.D., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318\u20132324. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z.", "ArticleIdList": ["10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z", "8635102"]}, {"Citation": "Britt K.L., Cuzick J., Phillips K.A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer. 2020;20:417\u2013436. doi: 10.1038/s41568-020-0266-x.", "ArticleIdList": ["10.1038/s41568-020-0266-x", "32528185"]}, {"Citation": "Hankinson S.E., Colditz G.A., Willett W.C. Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6:213\u2013218. doi: 10.1186/bcr921.", "ArticleIdList": ["10.1186/bcr921", "PMC549181", "15318928"]}, {"Citation": "Orrantia-Borunda E., Anchondo-Nu\u00f1ez P., Acu\u00f1a-Aguilar L.E., G\u00f3mez-Valles F.O., Ram\u00edrez-Valdespino C.A. Subtypes of Breast Cancer. In: Mayrovitz H.N., editor. Breast Cancer. Exon Publications; Brisbane, Australia: 2022. Chapter 3.", "ArticleIdList": ["10.36255/exon-publications-breast-cancer-subtypes", "36122153"]}, {"Citation": "Yin L., Duan J.J., Bian X.W., Yu S.C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. doi: 10.1186/s13058-020-01296-5.", "ArticleIdList": ["10.1186/s13058-020-01296-5", "PMC7285581", "32517735"]}, {"Citation": "SEER*Explorer: An Interactive Website for SEER Cancer Statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. Data Source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 Registries (Excluding Illinois and Massachusetts)  [(accessed on 20 April 2023)]; Available online:  https://seer.cancer.gov/statistics-network/explorer/"}, {"Citation": "Waks A.G., Winer E.P. Breast Cancer Treatment: A Review. JAMA. 2019;321:288\u2013300. doi: 10.1001/jama.2018.19323.", "ArticleIdList": ["10.1001/jama.2018.19323", "30667505"]}, {"Citation": "Asselain B., Barlow W., Bartlett J., Bergh J., Bergsten-Nordstr\u00f6m E., Bliss J., Boccardo F., Boddington C., Bogaerts J., Bonadonna G., et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27\u201339. doi: 10.1016/S1470-2045(17)30777-5.", "ArticleIdList": ["10.1016/S1470-2045(17)30777-5", "PMC5757427", "29242041"]}, {"Citation": "Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S., Khan S.A., Loibl S., Morris E.A., Perez A., et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol. 2021;39:1485\u20131505. doi: 10.1200/JCO.20.03399.", "ArticleIdList": ["10.1200/JCO.20.03399", "PMC8274745", "33507815"]}, {"Citation": "Jordan V.C. Tamoxifen: A most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003;2:205\u2013213. doi: 10.1038/nrd1031.", "ArticleIdList": ["10.1038/nrd1031", "12612646"]}, {"Citation": "Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u2013784. doi: 10.1016/S0140-6736(11)60993-8.", "ArticleIdList": ["10.1016/S0140-6736(11)60993-8", "PMC3163848", "21802721"]}, {"Citation": "Burstein H.J., Temin S., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Rowden D., Solky A.J., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 2014;32:2255\u20132269. doi: 10.1200/JCO.2013.54.2258.", "ArticleIdList": ["10.1200/JCO.2013.54.2258", "PMC4876310", "24868023"]}, {"Citation": "Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 1991;262:3\u201311.", "ArticleIdList": ["1984929"]}, {"Citation": "Waldman A.D., Fritz J.M., Lenardo M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol. 2020;20:651\u2013668. doi: 10.1038/s41577-020-0306-5.", "ArticleIdList": ["10.1038/s41577-020-0306-5", "PMC7238960", "32433532"]}, {"Citation": "Sanmamed M.F., Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2019;176:677. doi: 10.1016/j.cell.2019.01.008.", "ArticleIdList": ["10.1016/j.cell.2019.01.008", "30682374"]}, {"Citation": "Song X., Liu C., Wang N., Huang H., He S., Gong C., Wei Y. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv. Drug Deliv. Rev. 2021;168:158\u2013180. doi: 10.1016/j.addr.2020.04.010.", "ArticleIdList": ["10.1016/j.addr.2020.04.010", "32360576"]}, {"Citation": "Katti A., Diaz B.J., Caragine C.M., Sanjana N.E., Dow L.E. CRISPR in cancer biology and therapy. Nat. Rev. Cancer. 2022;22:259\u2013279. doi: 10.1038/s41568-022-00441-w.", "ArticleIdList": ["10.1038/s41568-022-00441-w", "35194172"]}, {"Citation": "Chen X.Z., Guo R., Zhao C., Xu J., Song H., Yu H., Pilarsky C., Nainu F., Li J.Q., Zhou X.K., et al. A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. Front. Pharmacol. 2022;13:939090. doi: 10.3389/fphar.2022.939090.", "ArticleIdList": ["10.3389/fphar.2022.939090", "PMC9353945", "35935840"]}, {"Citation": "Sharma P., Hu-Lieskovan S., Wargo J.A., Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u2013723. doi: 10.1016/j.cell.2017.01.017.", "ArticleIdList": ["10.1016/j.cell.2017.01.017", "PMC5391692", "28187290"]}, {"Citation": "Gupta S., Gupta S.C., Hunter K.D., Pant A.B. Immunotherapy: A New Hope for Cancer Patients. J. Oncol. 2020;2020:3548603. doi: 10.1155/2020/3548603.", "ArticleIdList": ["10.1155/2020/3548603", "PMC7368182", "32695164"]}, {"Citation": "Riley R.S., June C.H., Langer R., Mitchell M.J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 2019;18:175\u2013196. doi: 10.1038/s41573-018-0006-z.", "ArticleIdList": ["10.1038/s41573-018-0006-z", "PMC6410566", "30622344"]}, {"Citation": "Hegde P.S., Chen D.S. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52:17\u201335. doi: 10.1016/j.immuni.2019.12.011.", "ArticleIdList": ["10.1016/j.immuni.2019.12.011", "31940268"]}, {"Citation": "Gutwillig A., Santana-Magal N., Farhat-Younis L., Rasoulouniriana D., Madi A., Luxenburg C., Cohen J., Padmanabhan K., Shomron N., Shapira G., et al. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. eLife. 2022;11:e80315. doi: 10.7554/eLife.80315.", "ArticleIdList": ["10.7554/eLife.80315", "PMC9489212", "36124553"]}, {"Citation": "Hulsbergen A.F.C., Claes A., Kavouridis V.K., Ansaripour A., Nogarede C., Hughes M.E., Smith T.R., Brastianos P.K., Verhoeff J.J.C., Lin N.U., et al. Subtype switching in breast cancer brain metastases: A multicenter analysis. Neuro-Oncology. 2020;22:1173\u20131181. doi: 10.1093/neuonc/noaa013.", "ArticleIdList": ["10.1093/neuonc/noaa013", "PMC7471502", "31970416"]}, {"Citation": "McAnena P.F., McGuire A., Ramli A., Curran C., Malone C., McLaughlin R., Barry K., Brown J.A.L., Kerin M.J. Correction to: Breast cancer subtype discordance: Impact on post-recurrence survival and potential treatment options. BMC Cancer. 2018;18:282. doi: 10.1186/s12885-018-4174-3.", "ArticleIdList": ["10.1186/s12885-018-4174-3", "PMC5851151", "29534688"]}, {"Citation": "Thomford N.E., Senthebane D.A., Rowe A., Munro D., Seele P., Maroyi A., Dzobo K. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int. J. Mol. Sci. 2018;19:1578. doi: 10.3390/ijms19061578.", "ArticleIdList": ["10.3390/ijms19061578", "PMC6032166", "29799486"]}, {"Citation": "Wang S., Long S., Deng Z., Wu W. Positive Role of Chinese Herbal Medicine in Cancer Immune Regulation. Am. J. Chin. Med. 2020;48:1577\u20131592. doi: 10.1142/S0192415X20500780.", "ArticleIdList": ["10.1142/S0192415X20500780", "33202152"]}, {"Citation": "Nie J., Zhao C., Deng L.I., Chen J., Yu B., Wu X., Pang P., Chen X. Efficacy of traditional Chinese medicine in treating cancer. Biomed. Rep. 2016;4:3\u201314. doi: 10.3892/br.2015.537.", "ArticleIdList": ["10.3892/br.2015.537", "PMC4726876", "26870326"]}, {"Citation": "Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31\u201346. doi: 10.1158/2159-8290.CD-21-1059.", "ArticleIdList": ["10.1158/2159-8290.CD-21-1059", "35022204"]}, {"Citation": "Chen D.S., Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1\u201310. doi: 10.1016/j.immuni.2013.07.012.", "ArticleIdList": ["10.1016/j.immuni.2013.07.012", "23890059"]}, {"Citation": "Hiam-Galvez K.J., Allen B.M., Spitzer M.H. Systemic immunity in cancer. Nat. Rev. Cancer. 2021;21:345\u2013359. doi: 10.1038/s41568-021-00347-z.", "ArticleIdList": ["10.1038/s41568-021-00347-z", "PMC8034277", "33837297"]}, {"Citation": "Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002;3:991\u2013998. doi: 10.1038/ni1102-991.", "ArticleIdList": ["10.1038/ni1102-991", "12407406"]}, {"Citation": "Decker W.K., da Silva R.F., Sanabria M.H., Angelo L.S., Guimar\u00e3es F., Burt B.M., Kheradmand F., Paust S. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front. Immunol. 2017;8:829. doi: 10.3389/fimmu.2017.00829.", "ArticleIdList": ["10.3389/fimmu.2017.00829", "PMC5539135", "28824608"]}, {"Citation": "Thomas L. Discussion of cellular and humoral aspects of hypersensitive states. In: Lawrence H.S., editor. Cellular and Humoral Aspects of the Hypersensitive States. Hoeber-Harper; New York, NY, USA: 1959."}, {"Citation": "Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970;13:1\u201327. doi: 10.1159/000386035.", "ArticleIdList": ["10.1159/000386035", "4921480"]}, {"Citation": "Gasser S., Raulet D.H. The DNA damage response arouses the immune system. Cancer Res. 2006;66:3959\u20133962. doi: 10.1158/0008-5472.CAN-05-4603.", "ArticleIdList": ["10.1158/0008-5472.CAN-05-4603", "16618710"]}, {"Citation": "Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006;6:715\u2013727. doi: 10.1038/nri1936.", "ArticleIdList": ["10.1038/nri1936", "16977338"]}, {"Citation": "Dhar P., Wu J.D. NKG2D and its ligands in cancer. Curr. Opin. Immunol. 2018;51:55\u201361. doi: 10.1016/j.coi.2018.02.004.", "ArticleIdList": ["10.1016/j.coi.2018.02.004", "PMC6145810", "29525346"]}, {"Citation": "Lussier D.M., Schreiber R.D. Cancer immunosurveillance: Immunoediting. Immun. Pathog. Tumors. 2016;4:396\u2013405. doi: 10.1016/b978-0-12-374279-7.17001-8.", "ArticleIdList": ["10.1016/b978-0-12-374279-7.17001-8"]}, {"Citation": "Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137\u2013148. doi: 10.1016/j.immuni.2004.07.017.", "ArticleIdList": ["10.1016/j.immuni.2004.07.017", "15308095"]}, {"Citation": "O\u2019Donnell J.S., Teng M.W.L., Smyth M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019;16:151\u2013167. doi: 10.1038/s41571-018-0142-8.", "ArticleIdList": ["10.1038/s41571-018-0142-8", "30523282"]}, {"Citation": "Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107\u20131111. doi: 10.1038/35074122.", "ArticleIdList": ["10.1038/35074122", "11323675"]}, {"Citation": "Robinson D.R., Wu Y.M., Lonigro R.J., Vats P., Cobain E., Everett J., Cao X., Rabban E., Kumar-Sinha C., Raymond V., et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297\u2013303. doi: 10.1038/nature23306.", "ArticleIdList": ["10.1038/nature23306", "PMC5995337", "28783718"]}, {"Citation": "Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. doi: 10.1038/nature11412.", "ArticleIdList": ["10.1038/nature11412", "PMC3465532", "23000897"]}, {"Citation": "Anders C.K., Abramson V., Tan T., Dent R. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. Am. Soc. Clin. Oncol. Educ. Book. 2016;35:34\u201342. doi: 10.1200/EDBK_159135.", "ArticleIdList": ["10.1200/EDBK_159135", "27249684"]}, {"Citation": "Bianchini G., Balko J.M., Mayer I.A., Sanders M.E., Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016;13:674\u2013690. doi: 10.1038/nrclinonc.2016.66.", "ArticleIdList": ["10.1038/nrclinonc.2016.66", "PMC5461122", "27184417"]}, {"Citation": "Xiao Y., Ma D., Zhao S., Suo C., Shi J., Xue M.Z., Ruan M., Wang H., Zhao J., Li Q., et al. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clin. Cancer Res. 2019;25:5002\u20135014. doi: 10.1158/1078-0432.CCR-18-3524.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-3524", "30837276"]}, {"Citation": "Galluzzi L., Buqu\u00e9 A., Kepp O., Zitvogel L., Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017;17:97\u2013111. doi: 10.1038/nri.2016.107.", "ArticleIdList": ["10.1038/nri.2016.107", "27748397"]}, {"Citation": "Blankenstein T., Coulie P.G., Gilboa E., Jaffee E.M. The determinants of tumour immunogenicity. Nat. Rev. Cancer. 2012;12:307\u2013313. doi: 10.1038/nrc3246.", "ArticleIdList": ["10.1038/nrc3246", "PMC3552609", "22378190"]}, {"Citation": "Thomas A., Routh E.D., Pullikuth A., Jin G., Su J., Chou J.W., Hoadley K.A., Print C., Knowlton N., Black M.A., et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 2018;7:e1490854. doi: 10.1080/2162402X.2018.1490854.", "ArticleIdList": ["10.1080/2162402X.2018.1490854", "PMC6207420", "30386679"]}, {"Citation": "Wang S., He Z., Wang X., Li H., Liu X.S. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife. 2019;8:e49020. doi: 10.7554/eLife.49020.", "ArticleIdList": ["10.7554/eLife.49020", "PMC6879305", "31767055"]}, {"Citation": "Samstein R.M., Lee C.H., Shoushtari A.N., Hellmann M.D., Shen R., Janjigian Y.Y., Barron D.A., Zehir A., Jordan E.J., Omuro A., et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019;51:202\u2013206. doi: 10.1038/s41588-018-0312-8.", "ArticleIdList": ["10.1038/s41588-018-0312-8", "PMC6365097", "30643254"]}, {"Citation": "Lawlor R.T., Mattiolo P., Mafficini A., Hong S.M., Piredda M.L., Taormina S.V., Malleo G., Marchegiani G., Pea A., Salvia R., et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers. 2021;13:3119. doi: 10.3390/cancers13133119.", "ArticleIdList": ["10.3390/cancers13133119", "PMC8269341", "34206554"]}, {"Citation": "Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904\u20135912. doi: 10.1038/onc.2008.271.", "ArticleIdList": ["10.1038/onc.2008.271", "PMC3689267", "18836471"]}, {"Citation": "Ren X., Guo S., Guan X., Kang Y., Liu J., Yang X. Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy. Front. Immunol. 2022;13:790113. doi: 10.3389/fimmu.2022.790113.", "ArticleIdList": ["10.3389/fimmu.2022.790113", "PMC8918549", "35296094"]}, {"Citation": "Liu Y.T., Sun Z.J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u20135386. doi: 10.7150/thno.58390.", "ArticleIdList": ["10.7150/thno.58390", "PMC8039952", "33859752"]}, {"Citation": "Matsumoto H., Thike A.A., Li H., Yeong J., Koo S.L., Dent R.A., Tan P.H., Iqbal J. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res. Treat. 2016;156:237\u2013247. doi: 10.1007/s10549-016-3743-x.", "ArticleIdList": ["10.1007/s10549-016-3743-x", "26960711"]}, {"Citation": "Gao G., Wang Z., Qu X., Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: A systematic review and meta-analysis. BMC Cancer. 2020;20:179. doi: 10.1186/s12885-020-6668-z.", "ArticleIdList": ["10.1186/s12885-020-6668-z", "PMC7057662", "32131780"]}, {"Citation": "Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883\u2013899. doi: 10.1016/j.cell.2010.01.025.", "ArticleIdList": ["10.1016/j.cell.2010.01.025", "PMC2866629", "20303878"]}, {"Citation": "Labani-Motlagh A., Ashja-Mahdavi M., Loskog A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front. Immunol. 2020;11:940. doi: 10.3389/fimmu.2020.00940.", "ArticleIdList": ["10.3389/fimmu.2020.00940", "PMC7243284", "32499786"]}, {"Citation": "Gonzalez H., Hagerling C., Werb Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u20131284. doi: 10.1101/gad.314617.118.", "ArticleIdList": ["10.1101/gad.314617.118", "PMC6169832", "30275043"]}, {"Citation": "Salemme V., Centonze G., Cavallo F., Defilippi P., Conti L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front. Oncol. 2021;11:610303. doi: 10.3389/fonc.2021.610303.", "ArticleIdList": ["10.3389/fonc.2021.610303", "PMC7991834", "33777750"]}, {"Citation": "Xie F., Zhou X., Su P., Li H., Tu Y., Du J., Pan C., Wei X., Zheng M., Jin K., et al. Breast cancer cell-derived extracellular vesicles promote CD8+\u2009T cell exhaustion via TGF-\u03b2 type II receptor signaling. Nat. Commun. 2022;13:4461. doi: 10.1038/s41467-022-31250-2.", "ArticleIdList": ["10.1038/s41467-022-31250-2", "PMC9343611", "35915084"]}, {"Citation": "Rajput S., Wilber A. Roles of inflammation in cancer initiation, progression, and metastasis. Front. Biosci. 2010;2:176\u2013183. doi: 10.2741/s55.", "ArticleIdList": ["10.2741/s55", "20036938"]}, {"Citation": "Iyengar N.M., Hudis C.A., Dannenberg A.J. Obesity and inflammation: New insights into breast cancer development and progression. Am. Soc. Clin. Oncol. Educ. Book. 2013;33:46\u201351. doi: 10.14694/EdBook_AM.2013.33.46.", "ArticleIdList": ["10.14694/EdBook_AM.2013.33.46", "PMC3897299", "23714453"]}, {"Citation": "Dvorak H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986;315:1650\u20131659. doi: 10.1056/NEJM198612253152606.", "ArticleIdList": ["10.1056/NEJM198612253152606", "3537791"]}, {"Citation": "Greten F.R., Grivennikov S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27\u201341. doi: 10.1016/j.immuni.2019.06.025.", "ArticleIdList": ["10.1016/j.immuni.2019.06.025", "PMC6831096", "31315034"]}, {"Citation": "Zhao H., Wu L., Yan G., Chen Y., Zhou M., Wu Y., Li Y. Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 2021;6:263. doi: 10.1038/s41392-021-00658-5.", "ArticleIdList": ["10.1038/s41392-021-00658-5", "PMC8273155", "34248142"]}, {"Citation": "Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92\u2013101. doi: 10.1038/nature13479.", "ArticleIdList": ["10.1038/nature13479", "PMC4263681", "24899309"]}, {"Citation": "Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436\u2013444. doi: 10.1038/nature07205.", "ArticleIdList": ["10.1038/nature07205", "18650914"]}, {"Citation": "Hibino S., Kawazoe T., Kasahara H., Itoh S., Ishimoto T., Sakata-Yanagimoto M., Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int. J. Mol. Sci. 2021;22:5421. doi: 10.3390/ijms22115421.", "ArticleIdList": ["10.3390/ijms22115421", "PMC8196678", "34063828"]}, {"Citation": "Wellenstein M.D., Coffelt S.B., Duits D.E.M., van Miltenburg M.H., Slagter M., de Rink I., Henneman L., Kas S.M., Prekovic S., Hau C.S., et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572:538\u2013542. doi: 10.1038/s41586-019-1450-6.", "ArticleIdList": ["10.1038/s41586-019-1450-6", "PMC6707815", "31367040"]}, {"Citation": "Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420:860\u2013867. doi: 10.1038/nature01322.", "ArticleIdList": ["10.1038/nature01322", "PMC2803035", "12490959"]}, {"Citation": "Disis M.L. Immune regulation of cancer. J. Clin. Oncol. 2010;28:4531\u20134538. doi: 10.1200/JCO.2009.27.2146.", "ArticleIdList": ["10.1200/JCO.2009.27.2146", "PMC3041789", "20516428"]}, {"Citation": "DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212. doi: 10.1186/bcr1746.", "ArticleIdList": ["10.1186/bcr1746", "PMC2206719", "17705880"]}, {"Citation": "Li C., Jiang P., Wei S., Xu X., Wang J. Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer. 2020;19:116. doi: 10.1186/s12943-020-01234-1.", "ArticleIdList": ["10.1186/s12943-020-01234-1", "PMC7367382", "32680511"]}, {"Citation": "Zhou J., Wang G., Chen Y., Wang H., Hua Y., Cai Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J. Cell. Mol. Med. 2019;23:4854\u20134865. doi: 10.1111/jcmm.14356.", "ArticleIdList": ["10.1111/jcmm.14356", "PMC6653385", "31210425"]}, {"Citation": "Alzeibak R., Mishchenko T.A., Shilyagina N.Y., Balalaeva I.V., Vedunova M.V., Krysko D.V. Targeting immunogenic cancer cell death by photodynamic therapy: Past, present and future. J. Immunother. Cancer. 2021;9:e001926. doi: 10.1136/jitc-2020-001926.", "ArticleIdList": ["10.1136/jitc-2020-001926", "PMC7802670", "33431631"]}, {"Citation": "Garg A.D., Dudek A.M., Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? Biofactors. 2013;39:355\u2013367. doi: 10.1002/biof.1125.", "ArticleIdList": ["10.1002/biof.1125", "23900966"]}, {"Citation": "He X., Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u2013669. doi: 10.1038/s41422-020-0343-4.", "ArticleIdList": ["10.1038/s41422-020-0343-4", "PMC7395714", "32467592"]}, {"Citation": "Grywalska E., Pasiarski M., G\u00f3\u017ad\u017a S., Roli\u0144ski J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets Ther. 2018;11:6505\u20136524. doi: 10.2147/OTT.S150817.", "ArticleIdList": ["10.2147/OTT.S150817", "PMC6177399", "30323625"]}, {"Citation": "Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000;192:1027\u20131034. doi: 10.1084/jem.192.7.1027.", "ArticleIdList": ["10.1084/jem.192.7.1027", "PMC2193311", "11015443"]}, {"Citation": "Jiang X., Liu G., Li Y., Pan Y. Immune checkpoint: The novel target for antitumor therapy. Genes Dis. 2019;8:25\u201337. doi: 10.1016/j.gendis.2019.12.004.", "ArticleIdList": ["10.1016/j.gendis.2019.12.004", "PMC7859424", "33569511"]}, {"Citation": "Pentcheva-Hoang T., Egen J.G., Wojnoonski K., Allison J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004;21:401\u2013413. doi: 10.1016/j.immuni.2004.06.017.", "ArticleIdList": ["10.1016/j.immuni.2004.06.017", "15357951"]}, {"Citation": "Lao Y., Shen D., Zhang W., He R., Jiang M. Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance? Cancers. 2022;14:3575. doi: 10.3390/cancers14153575.", "ArticleIdList": ["10.3390/cancers14153575", "PMC9331941", "35892835"]}, {"Citation": "Qin S., Xu L., Yi M., Yu S., Wu K., Luo S. Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol. Cancer. 2019;18:155. doi: 10.1186/s12943-019-1091-2.", "ArticleIdList": ["10.1186/s12943-019-1091-2", "PMC6833286", "31690319"]}, {"Citation": "Uzhachenko R.V., Shanker A. CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front. Immunol. 2019;10:1906. doi: 10.3389/fimmu.2019.01906.", "ArticleIdList": ["10.3389/fimmu.2019.01906", "PMC6700470", "31456803"]}, {"Citation": "Zhou Y., Cheng L., Liu L., Li X. NK cells are never alone: Crosstalk and communication in tumour microenvironments. Mol. Cancer. 2023;22:34. doi: 10.1186/s12943-023-01737-7.", "ArticleIdList": ["10.1186/s12943-023-01737-7", "PMC9933398", "36797782"]}, {"Citation": "Ribas A., Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20131355. doi: 10.1126/science.aar4060.", "ArticleIdList": ["10.1126/science.aar4060", "PMC7391259", "29567705"]}, {"Citation": "Valenza C., Taurelli Salimbeni B., Santoro C., Trapani D., Antonarelli G., Curigliano G. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers. 2023;15:767. doi: 10.3390/cancers15030767.", "ArticleIdList": ["10.3390/cancers15030767", "PMC9913599", "36765724"]}, {"Citation": "Zhang X., Ge X., Jiang T., Yang R., Li S. Research progress on immunotherapy in triple-negative breast cancer (Review) Int. J. Oncol. 2022;61:95. doi: 10.3892/ijo.2022.5385.", "ArticleIdList": ["10.3892/ijo.2022.5385", "PMC9256074", "35762339"]}, {"Citation": "Thomas R., Al-Khadairi G., Decock J. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Front. Oncol. 2021;10:600573. doi: 10.3389/fonc.2020.600573.", "ArticleIdList": ["10.3389/fonc.2020.600573", "PMC7947906", "33718107"]}, {"Citation": "Dias D.A., Urban S., Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012;2:303\u2013336. doi: 10.3390/metabo2020303.", "ArticleIdList": ["10.3390/metabo2020303", "PMC3901206", "24957513"]}, {"Citation": "Carter G.T. Natural products and Pharma 2011: Strategic changes spur new opportunities. Nat. Prod. Rep. 2011;28:1783\u20131789. doi: 10.1039/c1np00033k.", "ArticleIdList": ["10.1039/c1np00033k", "21909580"]}, {"Citation": "Beutler J.A. Natural Products as a Foundation for Drug Discovery. Curr. Protoc. Pharmacol. 2019;86:e67. doi: 10.1002/cpph.67.", "ArticleIdList": ["10.1002/cpph.67", "PMC7442317", "31539923"]}, {"Citation": "Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012;75:311\u2013335. doi: 10.1021/np200906s.", "ArticleIdList": ["10.1021/np200906s", "PMC3721181", "22316239"]}, {"Citation": "Kongtawelert P., Wudtiwai B., Shwe T.H., Pothacharoen P., Phitak T. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer. Molecules. 2020;25:252. doi: 10.3390/molecules25020252.", "ArticleIdList": ["10.3390/molecules25020252", "PMC7024188", "31936263"]}, {"Citation": "Sulaiman G.M., Waheeb H.M., Jabir M.S., Khazaal S.H., Dewir Y.H., Naidoo Y. Hesperidin Loaded on Gold Nanoparticles as a Drug Delivery System for a Successful Biocompatible, Anti-Cancer, Anti-Inflammatory and Phagocytosis Inducer Model. Sci. Rep. 2020;10:9362. doi: 10.1038/s41598-020-66419-6.", "ArticleIdList": ["10.1038/s41598-020-66419-6", "PMC7283242", "32518242"]}, {"Citation": "Amalina N.D., Salsabila I.A., Zulfin U.M., Jenie R.I., Meiyanto E. In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells. J. Egypt Natl. Cancer Inst. 2023;35:6. doi: 10.1186/s43046-023-00166-3.", "ArticleIdList": ["10.1186/s43046-023-00166-3", "36967442"]}, {"Citation": "Saahene R.O., Wang J., Wang M.L., Agbo E., Pang D. The Antitumor Mechanism of Paeonol on CXCL4/CXCR3-B Signals in Breast Cancer Through Induction of Tumor Cell Apoptosis. Cancer Biother. Radiopharm. 2018;33:233\u2013240. doi: 10.1089/cbr.2018.2450.", "ArticleIdList": ["10.1089/cbr.2018.2450", "29847158"]}, {"Citation": "Wu J., Xue X., Zhang B., Cao H., Kong F., Jiang W., Li J., Sun D., Guo R. Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer. Tumour. Biol. 2016;37:12301\u201312313. doi: 10.1007/s13277-016-5088-9.", "ArticleIdList": ["10.1007/s13277-016-5088-9", "27272157"]}, {"Citation": "Noori S., Rezaei Tavirani M., Deravi N., Mahboobi Rabbani M.I., Zarghi A. Naringenin Enhances the Anti-Cancer Effect of Cyclophosphamide against MDA-MB-231 Breast Cancer Cells Via Targeting the STAT3 Signaling Pathway. Iran. J. Pharm. Res. 2020;19:122\u2013133. doi: 10.22037/ijpr.2020.113103.14112.", "ArticleIdList": ["10.22037/ijpr.2020.113103.14112", "PMC7757999", "33680016"]}, {"Citation": "Noori S., Nourbakhsh M., Imani H., Deravi N., Salehi N., Abdolvahabi Z. Naringenin and cryptotanshinone shift the immune response towards Th1 and modulate T regulatory cells via JAK2/STAT3 pathway in breast cancer. BMC Complement. Med. Ther. 2022;22:145. doi: 10.1186/s12906-022-03625-x.", "ArticleIdList": ["10.1186/s12906-022-03625-x", "PMC9125892", "35606804"]}, {"Citation": "Abaza M.S., Orabi K.Y., Al-Quattan E., Al-Attiyah R.J. Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer. Cancer Cell Int. 2015;15:46. doi: 10.1186/s12935-015-0194-0.", "ArticleIdList": ["10.1186/s12935-015-0194-0", "PMC4464250", "26074733"]}, {"Citation": "Zhang F., Dong W., Zeng W., Zhang L., Zhang C., Qiu Y., Wang L., Yin X., Zhang C., Liang W. Naringenin prevents TGF-\u03b21 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation. Breast Cancer Res. 2016;18:38. doi: 10.1186/s13058-016-0698-0.", "ArticleIdList": ["10.1186/s13058-016-0698-0", "PMC4818388", "27036297"]}, {"Citation": "Yuan B., Yao M., Wang X., Sato A., Okazaki A., Komuro H., Hayashi H., Toyoda H., Pei X., Hu X., et al. Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo. Cancer Cell Int. 2018;18:113. doi: 10.1186/s12935-018-0613-0.", "ArticleIdList": ["10.1186/s12935-018-0613-0", "PMC6090820", "30123091"]}, {"Citation": "Guo Y., Pei X. Tetrandrine-Induced Autophagy in MDA-MB-231 Triple-Negative Breast Cancer Cell through the Inhibition of PI3K/AKT/mTOR Signaling. Evid. Based Complement. Alternat. Med. 2019;2019:7517431. doi: 10.1155/2019/7517431.", "ArticleIdList": ["10.1155/2019/7517431", "PMC6332987", "30713576"]}, {"Citation": "Liu T., Li K., Zhang Z., Peng J., Yang J., Law B.Y.K., Liu X., Li W. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway. Am. J. Chin. Med. 2023;51:425\u2013444. doi: 10.1142/S0192415X23500222.", "ArticleIdList": ["10.1142/S0192415X23500222", "36692485"]}, {"Citation": "Li H., Tan G., Jiang X., Qiao H., Pan S., Jiang H., Kanwar J.R., Sun X. Therapeutic effects of matrine on primary and metastatic breast cancer. Am. J. Chin. Med. 2010;38:1115\u20131130. doi: 10.1142/S0192415X10008512.", "ArticleIdList": ["10.1142/S0192415X10008512", "21061465"]}, {"Citation": "Du J., Li J., Song D., Li Q., Li L., Li B., Li L. Matrine exerts anti-breast cancer activity by mediating apoptosis and protective autophagy via the AKT/mTOR pathway in MCF-7 cells. Mol. Med. Rep. 2020;22:3659\u20133666. doi: 10.3892/mmr.2020.11449.", "ArticleIdList": ["10.3892/mmr.2020.11449", "PMC7533454", "33000249"]}, {"Citation": "Zou Y., Sarem M., Xiang S., Hu H., Xu W., Shastri V.P. Autophagy inhibition enhances Matrine derivative MASM induced apoptosis in cancer cells via a mechanism involving reactive oxygen species-mediated PI3K/Akt/mTOR and Erk/p38 signaling. BMC Cancer. 2019;19:949. doi: 10.1186/s12885-019-6199-7.", "ArticleIdList": ["10.1186/s12885-019-6199-7", "PMC6794878", "31615459"]}, {"Citation": "Lao Y. Clinical study of matrine injection on preventing liver function damage of anti-tumor drugs during chemotherapy of breast cancer. Zhong Yao Cai. 2005;28:735\u2013737. (In Chinese)", "ArticleIdList": ["16379429"]}, {"Citation": "Varghese E., Samuel S.M., Varghese S., Cheema S., Mamtani R., B\u00fcsselberg D. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells. Biomolecules. 2018;8:163. doi: 10.3390/biom8040163.", "ArticleIdList": ["10.3390/biom8040163", "PMC6315979", "30563138"]}, {"Citation": "Luo Y., Li J., Hu Y., Leung G.P.H., Geng F., Fu C., Zhang J. Injectable thermo-responsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on \u201ctwo strikes\u201d effects. Acta Pharm. Sin. B. 2020;10:2227\u20132245. doi: 10.1016/j.apsb.2020.05.011.", "ArticleIdList": ["10.1016/j.apsb.2020.05.011", "PMC7715064", "33304788"]}, {"Citation": "Tohkayomatee R., Reabroi S., Tungmunnithum D., Parichatikanond W., Pinthong D. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-\u03b1 Receptor and PI3K/AKT/mTOR Signaling. Molecules. 2022;27:3544. doi: 10.3390/molecules27113544.", "ArticleIdList": ["10.3390/molecules27113544", "PMC9182433", "35684480"]}, {"Citation": "Zhai Z., Qu X., Li H., Ouyang Z., Yan W., Liu G., Liu X., Fan Q., Tang T., Dai K., et al. Inhibition of MDA-MB-231 breast cancer cell migration and invasion activity by andrographolide via suppression of nuclear factor-\u03baB-dependent matrix metalloproteinase-9 expression. Mol. Med. Rep. 2015;11:1139\u20131145. doi: 10.3892/mmr.2014.2872.", "ArticleIdList": ["10.3892/mmr.2014.2872", "PMC6413764", "25374279"]}, {"Citation": "Li J., Huang L., He Z., Chen M., Ding Y., Yao Y., Duan Y., Zixuan L., Qi C., Zheng L., et al. Andrographolide Suppresses the Growth and Metastasis of Luminal-Like Breast Cancer by Inhibiting the NF-\u03baB/miR-21-5p/PDCD4 Signaling Pathway. Front. Cell Dev. Biol. 2021;9:643525. doi: 10.3389/fcell.2021.643525.", "ArticleIdList": ["10.3389/fcell.2021.643525", "PMC8261247", "34249905"]}, {"Citation": "Zhou J., Ong C.N., Hur G.M., Shen H.M. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem. Pharmacol. 2010;79:1242\u20131250. doi: 10.1016/j.bcp.2009.12.014.", "ArticleIdList": ["10.1016/j.bcp.2009.12.014", "20026083"]}, {"Citation": "Hsu W.J., Lin M.H., Kuo T.C., Chou C.M., Mi F.L., Cheng C.H., Lin C.W. Fucoidan from Laminaria japonica exerts antitumor effects on angiogenesis and micrometastasis in triple-negative breast cancer cells. Int. J. Biol. Macromol. 2020;149:600\u2013608. doi: 10.1016/j.ijbiomac.2020.01.256.", "ArticleIdList": ["10.1016/j.ijbiomac.2020.01.256", "32004612"]}, {"Citation": "Hsu H.Y., Lin T.Y., Hwang P.A., Tseng L.M., Chen R.H., Tsao S.M., Hsu J. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGF\u03b2 receptor degradation in breast cancer. Carcinogenesis. 2013;34:874\u2013884. doi: 10.1093/carcin/bgs396.", "ArticleIdList": ["10.1093/carcin/bgs396", "23275155"]}, {"Citation": "Pawar V.K., Singh Y., Sharma K., Shrivastav A., Sharma A., Singh A., Meher J.G., Singh P., Raval K., Kumar A., et al. Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin. Int. J. Biol. Macromol. 2019;122:1100\u20131114. doi: 10.1016/j.ijbiomac.2018.09.059.", "ArticleIdList": ["10.1016/j.ijbiomac.2018.09.059", "30219515"]}, {"Citation": "Chen L.M., Yang P.P., Al Haq A.T., Hwang P.A., Lai Y.C., Weng Y.S., Chen M.A., Hsu H.L. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. J. Biomed. Sci. 2022;29:70. doi: 10.1186/s12929-022-00855-6.", "ArticleIdList": ["10.1186/s12929-022-00855-6", "PMC9479298", "36109724"]}, {"Citation": "Groult H., Cousin R., Chot-Plassot C., Maura M., Bridiau N., Piot J.M., Maugard T., Fruitier-Arnaudin I. \u03bb-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration. Mar. Drugs. 2019;17:140. doi: 10.3390/md17030140.", "ArticleIdList": ["10.3390/md17030140", "PMC6471403", "30818840"]}, {"Citation": "Cousin R., Groult H., Manseur C., Ferru-Cl\u00e9ment R., Gani M., Havret R., Toucheteau C., Prunier G., Colin B., Morel F., et al. A Marine \u03bb-Oligocarrageenan Inhibits Migratory and Invasive Ability of MDA-MB-231 Human Breast Cancer Cells through Actions on Heparanase Metabolism and MMP-14/MMP-2 Axis. Mar. Drugs. 2021;19:546. doi: 10.3390/md19100546.", "ArticleIdList": ["10.3390/md19100546", "PMC8539239", "34677445"]}, {"Citation": "Jazzara M., Ghannam A., Soukkarieh C., Murad H. Anti-Proliferative Activity of \u03bb-Carrageenan Through the Induction of Apoptosis in Human Breast Cancer Cells. Iran. J. Cancer Prev. 2016;9:e3836. doi: 10.17795/ijcp-3836.", "ArticleIdList": ["10.17795/ijcp-3836", "PMC5055760", "27761203"]}, {"Citation": "Luo M., Shao B., Nie W., Wei X.W., Li Y.L., Wang B.L., He Z.Y., Liang X., Ye T.H., Wei Y.Q. Antitumor and Adjuvant Activity of \u03bb-carrageenan by Stimulating Immune Response in Cancer Immunotherapy. Sci. Rep. 2015;5:11062. doi: 10.1038/srep11062.", "ArticleIdList": ["10.1038/srep11062", "PMC4476469", "26098663"]}, {"Citation": "Sun M., Ye Y., Xiao L., Duan X., Zhang Y., Zhang H. Anticancer effects of ginsenoside Rg3 (Review) Int. J. Mol. Med. 2017;39:507\u2013518. doi: 10.3892/ijmm.2017.2857.", "ArticleIdList": ["10.3892/ijmm.2017.2857", "28098857"]}, {"Citation": "Kim B.M., Kim D.H., Park J.H., Surh Y.J., Na H.K. Ginsenoside Rg3 Inhibits Constitutive Activation of NF-\u03baB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets. J. Cancer Prev. 2014;19:23\u201330. doi: 10.15430/JCP.2014.19.1.23.", "ArticleIdList": ["10.15430/JCP.2014.19.1.23", "PMC4189477", "25337569"]}, {"Citation": "Yang L.Q., Wang B., Gan H., Fu S.T., Zhu X.X., Wu Z.N., Zhan D.W., Gu R.L., Dou G.F., Meng Z.Y. Enhanced oral bioavailability and anti-tumor effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo. Biopharm. Drug Dispos. 2012;33:425\u2013436. doi: 10.1002/bdd.1806.", "ArticleIdList": ["10.1002/bdd.1806", "22898996"]}, {"Citation": "Yuan Z., Jiang H., Zhu X., Liu X., Li J. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-\u03baB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Biomed. Pharmacother. 2017;89:227\u2013232. doi: 10.1016/j.biopha.2017.02.038.", "ArticleIdList": ["10.1016/j.biopha.2017.02.038", "28231544"]}, {"Citation": "Wang P., Song D., Wan D., Li L., Mei W., Li X., Han L., Zhu X., Yang L., Cai Y., et al. Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-\u03baB and ERK pathways. PeerJ. 2020;8:e9281. doi: 10.7717/peerj.9281.", "ArticleIdList": ["10.7717/peerj.9281", "PMC7275687", "32547883"]}, {"Citation": "Wu H., Wei G., Luo L., Li L., Gao Y., Tan X., Wang S., Chang H., Liu Y., Wei Y., et al. Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody. Biomater. Res. 2022;26:77. doi: 10.1186/s40824-022-00329-8.", "ArticleIdList": ["10.1186/s40824-022-00329-8", "PMC9733157", "36494759"]}, {"Citation": "Yue G.G., Xie S., Lee J.K., Kwok H.F., Gao S., Nian Y., Wu X.X., Wong C.K., Qiu M.H., Lau C.B. New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment. Sci. Rep. 2016;6:35263. doi: 10.1038/srep35263.", "ArticleIdList": ["10.1038/srep35263", "PMC5059658", "27731376"]}, {"Citation": "Wu X.X., Yue G.G., Dong J.R., Lam C.W., Wong C.K., Qiu M.H., Lau C.B. Actein Inhibits the Proliferation and Adhesion of Human Breast Cancer Cells and Suppresses Migration in vivo. Front. Pharmacol. 2018;9:1466. doi: 10.3389/fphar.2018.01466.", "ArticleIdList": ["10.3389/fphar.2018.01466", "PMC6299023", "30618758"]}, {"Citation": "Panche A.N., Diwan A.D., Chandra S.R. Flavonoids: An overview. J. Nutr. Sci. 2016;5:e47. doi: 10.1017/jns.2016.41.", "ArticleIdList": ["10.1017/jns.2016.41", "PMC5465813", "28620474"]}, {"Citation": "Maleki S.J., Crespo J.F., Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chem. 2019;299:125124. doi: 10.1016/j.foodchem.2019.125124.", "ArticleIdList": ["10.1016/j.foodchem.2019.125124", "31288163"]}, {"Citation": "Li C., Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit. Rev. Food Sci. Nutr. 2017;57:613\u2013631. doi: 10.1080/10408398.2014.906382.", "ArticleIdList": ["10.1080/10408398.2014.906382", "25675136"]}, {"Citation": "Ahmadi A., Shadboorestan A. Oxidative stress and cancer; the role of hesperidin, a citrus natural bioflavonoid, as a cancer chemoprotective agent. Nutr. Cancer. 2016;68:29\u201339. doi: 10.1080/01635581.2015.1078822.", "ArticleIdList": ["10.1080/01635581.2015.1078822", "26381129"]}, {"Citation": "Jia Y., Guo H., Cheng X., Zhang Y., Si M., Shi J., Ma D. Hesperidin protects against cisplatin-induced cardiotoxicity in mice by regulating the p62-Keap1-Nrf2 pathway. Food Funct. 2022;13:4205\u20134215. doi: 10.1039/D2FO00298A.", "ArticleIdList": ["10.1039/D2FO00298A", "35332348"]}, {"Citation": "Zhang L., Li D.C., Liu L.F. Paeonol: Pharmacological effects and mechanisms of action. Int. Immunopharmacol. 2019;72:413\u2013421. doi: 10.1016/j.intimp.2019.04.033.", "ArticleIdList": ["10.1016/j.intimp.2019.04.033", "31030097"]}, {"Citation": "Guo K., Feng G., Yan Q., Sun L., Zhang K., Shen F., Shen M., Ruan S. CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members. Mol. Med. Rep. 2019;20:4791\u20134802. doi: 10.3892/mmr.2019.10784.", "ArticleIdList": ["10.3892/mmr.2019.10784", "PMC6854604", "31702806"]}, {"Citation": "Chen X., Xu Z., Lu M., Ding W., Zhong J., Deng S., Li S., Miao J., Liu X., Wen Q., et al. Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p. Biochem. Biophys. Res. Commun. 2023;656:86\u201396. doi: 10.1016/j.bbrc.2023.03.005.", "ArticleIdList": ["10.1016/j.bbrc.2023.03.005", "36958259"]}, {"Citation": "Adki K.M., Kulkarni Y.A. Chemistry, pharmacokinetics, pharmacology and recent novel drug delivery systems of paeonol. Life Sci. 2020;250:117544. doi: 10.1016/j.lfs.2020.117544.", "ArticleIdList": ["10.1016/j.lfs.2020.117544", "32179072"]}, {"Citation": "Motallebi M., Bhia M., Rajani H.F., Bhia I., Tabarraei H., Mohammadkhani N., Pereira-Silva M., Kasaii M.S., Nouri-Majd S., Mueller A., et al. Naringenin: A potential flavonoid phytochemical for cancer therapy. Life Sci. 2022;305:120752. doi: 10.1016/j.lfs.2022.120752.", "ArticleIdList": ["10.1016/j.lfs.2022.120752", "35779626"]}, {"Citation": "Zeng W., Jin L., Zhang F., Zhang C., Liang W. Naringenin as a potential immunomodulator in therapeutics. Pharmacol. Res. 2018;135:122\u2013126. doi: 10.1016/j.phrs.2018.08.002.", "ArticleIdList": ["10.1016/j.phrs.2018.08.002", "30081177"]}, {"Citation": "Qin L., Jin L., Lu L., Lu X., Zhang C., Zhang F., Liang W. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell. 2011;2:507\u2013516. doi: 10.1007/s13238-011-1056-8.", "ArticleIdList": ["10.1007/s13238-011-1056-8", "PMC4875175", "21748601"]}, {"Citation": "Minami H., Kim J.S., Ikezawa N., Takemura T., Katayama T., Kumagai H., Sato F. Microbial production of plant benzylisoquinoline alkaloids. Proc. Natl. Acad. Sci. USA. 2008;105:7393\u20137398. doi: 10.1073/pnas.0802981105.", "ArticleIdList": ["10.1073/pnas.0802981105", "PMC2396723", "18492807"]}, {"Citation": "Matsuura H.N., Fett-Neto A.G. Plant Toxins. Plant Alkaloids: Main Features, Toxicity, and Mechanisms of Action. In: Gopalakrishnakone P., Carlini C., Ligabue-Braun R., editors. Toxinology. Springer; Dordrecht, The Netherlands: 2015.", "ArticleIdList": ["10.1007/978-94-007-6728-7_2-1"]}, {"Citation": "Heinrich M., Mah J., Amirkia V. Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity-An Update and Forward Look. Molecules. 2021;26:1836. doi: 10.3390/molecules26071836.", "ArticleIdList": ["10.3390/molecules26071836", "PMC8036335", "33805869"]}, {"Citation": "Chen S., Liu Y., Ge J., Yin J., Shi T., Ntambara J., Cheng Z., Chu M., Gu H. Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19. Medicina. 2022;58:1194. doi: 10.3390/medicina58091194.", "ArticleIdList": ["10.3390/medicina58091194", "PMC9503147", "36143871"]}, {"Citation": "Wu W.H., Feng Y.H., Min C.Y., Zhou S.W., Chen Z.D., Huang L.M., Yang W.L., Yang G.H., Li J., Shi J., et al. Clinical efficacy of tetrandrine in artificial stone-associated silicosis: A retrospective cohort study. Front. Med. 2023;10:1107967. doi: 10.3389/fmed.2023.1107967.", "ArticleIdList": ["10.3389/fmed.2023.1107967", "PMC9981789", "36873890"]}, {"Citation": "Luan F., He X., Zeng N. Tetrandrine: A review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems. J. Pharm. Pharmacol. 2020;72:1491\u20131512. doi: 10.1111/jphp.13339.", "ArticleIdList": ["10.1111/jphp.13339", "32696989"]}, {"Citation": "Li J., Cheng X.Y., Yang H., Li L., Niu Y., Yu J.Q., Li W.Q., Yao Y. Matrine ameliorates cognitive deficits via inhibition of microglia mediated neuroinflammation in an Alzheimer\u2019s disease mouse model. Pharmazie. 2020;75:344\u2013347.", "ArticleIdList": ["32635978"]}, {"Citation": "He X., Fang J., Huang L., Wang J., Huang X. Sophora flavescens Ait.: Traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. J. Ethnopharmacol. 2015;172:10\u201329. doi: 10.1016/j.jep.2015.06.010.", "ArticleIdList": ["10.1016/j.jep.2015.06.010", "26087234"]}, {"Citation": "Chen M., Ding Y., Tong Z. Efficacy and Safety of Sophora flavescens (Kushen) Based Traditional Chinese Medicine in the Treatment of Ulcerative Colitis: Clinical Evidence and Potential Mechanisms. Front. Pharmacol. 2020;11:603476. doi: 10.3389/fphar.2020.603476.", "ArticleIdList": ["10.3389/fphar.2020.603476", "PMC7758483", "33362558"]}, {"Citation": "Zhang H., Chen L., Sun X., Yang Q., Wan L., Guo C. Matrine: A Promising Natural Product With Various Pharmacological Activities. Front. Pharmacol. 2020;11:588. doi: 10.3389/fphar.2020.00588.", "ArticleIdList": ["10.3389/fphar.2020.00588", "PMC7232545", "32477114"]}, {"Citation": "Chi G., Xu D., Zhang B., Yang F. Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075/BCL-9. Chem. Biol. Interact. 2019;308:198\u2013205. doi: 10.1016/j.cbi.2019.05.030.", "ArticleIdList": ["10.1016/j.cbi.2019.05.030", "31112718"]}, {"Citation": "Zhang J.Q., Li Y.M., Liu T., He W.T., Chen Y.T., Chen X.H., Li X., Zhou W.C., Yi J.F., Ren Z.J. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J. Gastroenterol. 2010;16:4281\u20134290. doi: 10.3748/wjg.v16.i34.4281.", "ArticleIdList": ["10.3748/wjg.v16.i34.4281", "PMC2937108", "20818811"]}, {"Citation": "Yang Y., Lu Y., Pei T., Guo B., Li J., Wang H., Ba Q. Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. Pharmacol. Res.\u2014Mod. Chin. Med. 2022;3:100108. doi: 10.1016/j.prmcm.2022.100108.", "ArticleIdList": ["10.1016/j.prmcm.2022.100108"]}, {"Citation": "Wang W., You R.L., Qin W.J., Hai L.N., Fang M.J., Huang G.H., Kang R.X., Li M.H., Qiao Y.F., Li J.W., et al. Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacol. Sin. 2015;36:676\u2013679. doi: 10.1038/aps.2015.24.", "ArticleIdList": ["10.1038/aps.2015.24", "PMC4594177", "25982630"]}, {"Citation": "Chen H., Yao X., Li T., Lam C.W., Zhang R., Zhang H., Wang J., Zhang W., Leung E.L., Wu Q. Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines. J. Cancer. 2020;11:1883\u20131898. doi: 10.7150/jca.40267.", "ArticleIdList": ["10.7150/jca.40267", "PMC7052862", "32194799"]}, {"Citation": "Ao M., Xiao X., Li Q. Efficacy and safety of compound Kushen injection combined with chemotherapy on postoperative Patients with breast cancer: A meta-analysis of randomized controlled trials. Medicine. 2019;98:e14024. doi: 10.1097/MD.0000000000014024.", "ArticleIdList": ["10.1097/MD.0000000000014024", "PMC6370033", "30653109"]}, {"Citation": "Lai B.Y., Chu A.J., Yu B.W., Jia L.Y., Fan Y.Y., Liu J.P., Pei X.H. Clinical Effectiveness and Safety of Chinese Herbal Medicine Compound Kushen Injection as an Add-On Treatment for Breast Cancer: A Systematic Review and Meta-Analysis. Evid. Based Complement. Alternat. Med. 2022;2022:8118408. doi: 10.1155/2022/8118408.", "ArticleIdList": ["10.1155/2022/8118408", "PMC8763510", "35047051"]}, {"Citation": "Boncan D.A.T., Tsang S.S.K., Li C., Lee I.H.T., Lam H.M., Chan T.F., Hui J.H.L. Terpenes and Terpenoids in Plants: Interactions with Environment and Insects. Int. J. Mol. Sci. 2020;21:7382. doi: 10.3390/ijms21197382.", "ArticleIdList": ["10.3390/ijms21197382", "PMC7583029", "33036280"]}, {"Citation": "N\u00fa\u00f1ez-Pons L., Shilling A., Verde C., Baker B.J., Giordano D. Marine Terpenoids from Polar Latitudes and Their Potential Applications in Biotechnology. Mar. Drugs. 2020;18:401. doi: 10.3390/md18080401.", "ArticleIdList": ["10.3390/md18080401", "PMC7459527", "32751369"]}, {"Citation": "Masyita A., Mustika Sari R., Dwi Astuti A., Yasir B., Rahma Rumata N., Emran T.B., Nainu F., Simal-Gandara J. Terpenes and terpenoids as main bioactive compounds of essential oils, their roles in human health and potential application as natural food preservatives. Food Chem. X. 2022;13:100217. doi: 10.1016/j.fochx.2022.100217.", "ArticleIdList": ["10.1016/j.fochx.2022.100217", "PMC9039924", "35498985"]}, {"Citation": "Cox-Georgian D., Ramadoss N., Dona C., Basu C. Medicinal Plants. Springer; Cham, Switzerland: 2019. Therapeutic and Medicinal Uses of Terpenes; pp. 333\u2013359.", "ArticleIdList": ["10.1007/978-3-030-31269-5_15"]}, {"Citation": "Chen B.J. Triptolide, a Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook F. Leuk. Lymphoma. 2001;42:253\u2013265. doi: 10.3109/10428190109064582.", "ArticleIdList": ["10.3109/10428190109064582", "11699390"]}, {"Citation": "Kuo C.S., Yang C.Y., Lin C.K., Lin G.J., Sytwu H.K., Chen Y.W. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-\u03b3-modulated microenvironment in vitro, in vivo, and in clinical patients. Biomed. Pharmacother. 2021;133:111057. doi: 10.1016/j.biopha.2020.111057.", "ArticleIdList": ["10.1016/j.biopha.2020.111057", "33378962"]}, {"Citation": "Zhang L., Yu J.S. Triptolide reverses helper T cell inhibition and down-regulates IFN-\u03b3 induced PD-L1 expression in glioma cell lines. J. Neurooncol. 2019;143:429\u2013436. doi: 10.1007/s11060-019-03193-0.", "ArticleIdList": ["10.1007/s11060-019-03193-0", "PMC6628928", "31152305"]}, {"Citation": "Cheng Y., Zhao Y., Zheng Y. Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity. Chin. Med. 2021;16:114. doi: 10.1186/s13020-021-00525-z.", "ArticleIdList": ["10.1186/s13020-021-00525-z", "PMC8572577", "34743749"]}, {"Citation": "Lu J., Ma Y., Wu J., Huang H., Wang X., Chen Z., Chen J., He H., Huang C. A review for the neuroprotective effects of andrographolide in the central nervous system. Biomed. Pharmacother. 2019;117:109078. doi: 10.1016/j.biopha.2019.109078.", "ArticleIdList": ["10.1016/j.biopha.2019.109078", "31181444"]}, {"Citation": "Tan W.S.D., Liao W., Zhou S., Wong W.S.F. Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action. Biochem. Pharmacol. 2017;139:71\u201381. doi: 10.1016/j.bcp.2017.03.024.", "ArticleIdList": ["10.1016/j.bcp.2017.03.024", "28377280"]}, {"Citation": "Beesetti S.L., Jayadev M., Subhashini G.V., Mansour L., Alwasel S., Harrath A.H. Andrographolide as a Therapeutic Agent Against Breast and Ovarian Cancers. Open Life Sci. 2019;14:462\u2013469. doi: 10.1515/biol-2019-0052.", "ArticleIdList": ["10.1515/biol-2019-0052", "PMC7874781", "33817182"]}, {"Citation": "Yue G.G., Gomes A.J., Saeed M.E.M., Tsui K.Y., Dawood M., Drif A.I., Wong E.C., Lee W.F., Liu W., Chiu P.W., et al. Identification of active components in Andrographis paniculata targeting on CD81 in esophageal cancer in vitro and in vivo. Phytomedicine. 2022;102:154183. doi: 10.1016/j.phymed.2022.154183.", "ArticleIdList": ["10.1016/j.phymed.2022.154183", "35636176"]}, {"Citation": "Liu J., Willf\u00f6r S., Xu C. A review of bioactive plant polysaccharides: Biological activities, functionalization, and biomedical applications. Bioact. Carbohydrates Diet. Fibre. 2015;5:31\u201361. doi: 10.1016/j.bcdf.2014.12.001.", "ArticleIdList": ["10.1016/j.bcdf.2014.12.001"]}, {"Citation": "Gan L., Wang J., Guo Y. Poylsaccharides influence human health via microbiota-dependent and independent pathways. Front. Nutr. 2022;9:2022. doi: 10.3389/fnut.2022.1030063.", "ArticleIdList": ["10.3389/fnut.2022.1030063", "PMC9682087", "36438731"]}, {"Citation": "Tzianabos A.O. Polysaccharide immunomodulators as therapeutic agents: Structural aspects and biologic function. Clin. Microbiol. Rev. 2000;13:523\u2013533. doi: 10.1128/CMR.13.4.523.", "ArticleIdList": ["10.1128/CMR.13.4.523", "PMC88946", "11023954"]}, {"Citation": "Hsu H.Y., Hwang P.A. Clinical applications of fucoidan in translational medicine for adjuvant cancer therapy. Clin. Transl. Med. 2019;8:15. doi: 10.1186/s40169-019-0234-9.", "ArticleIdList": ["10.1186/s40169-019-0234-9", "PMC6491526", "31041568"]}, {"Citation": "Jiao G., Yu G., Zhang J., Ewart H.S. Chemical structures and bioactivities of sulfated polysaccharides from marine algae. Mar. Drugs. 2011;9:196\u2013223. doi: 10.3390/md9020196.", "ArticleIdList": ["10.3390/md9020196", "PMC3093253", "21566795"]}, {"Citation": "Liang W., Mao X., Peng X., Tang S. Effects of sulfate group in red seaweed polysaccharides on anticoagulant activity and cytotoxicity. Carbohydr. Polym. 2014;101:776\u2013785. doi: 10.1016/j.carbpol.2013.10.010.", "ArticleIdList": ["10.1016/j.carbpol.2013.10.010", "24299838"]}, {"Citation": "Jagtap A.S., Manohar C.S. Overview on Microbial Enzymatic Production of Algal Oligosaccharides for Nutraceutical Applications. Mar. Biotechnol. 2021;23:159\u2013176. doi: 10.1007/s10126-021-10027-6.", "ArticleIdList": ["10.1007/s10126-021-10027-6", "33763808"]}, {"Citation": "Rao A.V., Gurfinkel D.M. The bioactivity of saponins: Triterpenoid and steroidal glycosides. Drug Metabol. Drug Interact. 2000;17:211\u2013235. doi: 10.1515/DMDI.2000.17.1-4.211.", "ArticleIdList": ["10.1515/DMDI.2000.17.1-4.211", "11201296"]}, {"Citation": "Moghimipour E., Handali S. Saponins: Properties, Methods of Evaluation and Applications. ARRB. 2015;5:207\u2013220. doi: 10.9734/ARRB/2015/11674.", "ArticleIdList": ["10.9734/ARRB/2015/11674"]}, {"Citation": "Mugford S.T., Osbourn A. Isoprenoid Synthesis in Plants and Microorganisms. Springer; Berlin/Heidelberg, Germany: 2012. Saponin Synthesis and Function; pp. 405\u2013424.", "ArticleIdList": ["10.1007/978-1-4614-4063-5_28"]}, {"Citation": "Park J.D., Rhee D.K., Lee Y.H. Biological Activities and Chemistry of Saponins from Panax ginseng C. A. Meyer. Phytochem. Rev. 2005;4:159\u2013175. doi: 10.1007/s11101-005-2835-8.", "ArticleIdList": ["10.1007/s11101-005-2835-8"]}, {"Citation": "Choi J.S., Chun K.S., Kundu J., Kundu J.K. Biochemical basis of cancer chemoprevention and/or chemotherapy with ginsenosides (Review) Int. J. Mol. Med. 2013;32:1227\u20131238. doi: 10.3892/ijmm.2013.1519.", "ArticleIdList": ["10.3892/ijmm.2013.1519", "24126942"]}, {"Citation": "Surh Y.J., Na H.K., Lee J.Y., Keum Y.S. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng, C.A. Meyer. J. Korean Med. Sci. 2001;16:S38\u2013S41. doi: 10.3346/jkms.2001.16.S.S38.", "ArticleIdList": ["10.3346/jkms.2001.16.S.S38", "PMC3202206", "11748375"]}, {"Citation": "Wang H., Zheng Y., Sun Q., Zhang Z., Zhao M., Peng C., Shi S. Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies. J. Nanobiotechnol. 2021;19:322. doi: 10.1186/s12951-021-01062-5.", "ArticleIdList": ["10.1186/s12951-021-01062-5", "PMC8518152", "34654430"]}, {"Citation": "Miao L., Ma H., Dong T., Zhao C., Gao T., Wu T., Xu H., Zhang J. Ginsenoside Rg3 liposomes regulate tumor microenvironment for the treatment of triple negative breast cancer. Drug Dev. Ind. Pharm. 2023;49:139\u2013148. doi: 10.1080/03639045.2023.2188078.", "ArticleIdList": ["10.1080/03639045.2023.2188078", "36881020"]}, {"Citation": "Zuo S., Wang J., An X., Wang Z., Zheng X., Zhang Y. Fabrication of Ginsenoside-Based Nanodrugs for Enhanced Antitumor Efficacy on Triple-Negative Breast Cancer. Front. Bioeng. Biotechnol. 2022;10:945472. doi: 10.3389/fbioe.2022.945472.", "ArticleIdList": ["10.3389/fbioe.2022.945472", "PMC9412961", "36032706"]}, {"Citation": "Guo Y., Yin T., Wang X., Zhang F., Pan G., Lv H., Wang X., Owoicho Orgah J., Zhu Y., Wu H. Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: A review. J. Ethnopharmacol. 2017;209:264\u2013282. doi: 10.1016/j.jep.2017.07.040.", "ArticleIdList": ["10.1016/j.jep.2017.07.040", "28826891"]}, {"Citation": "Rhyu M.R., Lu J., Webster D.E., Fabricant D.S., Farnsworth N.R., Wang Z.J. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J. Agric. Food Chem. 2006;54:9852\u20139857. doi: 10.1021/jf062808u.", "ArticleIdList": ["10.1021/jf062808u", "PMC2547488", "17177511"]}, {"Citation": "Sakurai N., Wu J.H., Sashida Y., Mimaki Y., Nikaido T., Koike K., Itokawa H., Lee K.H. Anti-AIDS agents. Part 57: Actein, an anti-HIV principle from the rhizome of Cimicifuga racemosa (black cohosh), and the anti-HIV activity of related saponins. Bioorg. Med. Chem. Lett. 2004;14:1329\u20131332. doi: 10.1016/j.bmcl.2003.12.035.", "ArticleIdList": ["10.1016/j.bmcl.2003.12.035", "14980692"]}, {"Citation": "Zhang H., Chen Y., Huang S., Xiao W.W., Qiu M.H., Shao L.D., Chen C.H., Li D. Development of actein derivatives as potent anti-triple negative breast cancer agents. Bioorg Med. Chem. Lett. 2023;89:129307. doi: 10.1016/j.bmcl.2023.129307.", "ArticleIdList": ["10.1016/j.bmcl.2023.129307", "37121522"]}, {"Citation": "Fiorentino S., Urue\u00f1a C., Lasso P., Prieto K., Barreto A. Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells. Front. Oncol. 2020;10:1334. doi: 10.3389/fonc.2020.01334.", "ArticleIdList": ["10.3389/fonc.2020.01334", "PMC7426739", "32850424"]}, {"Citation": "Zhu Y., Ouyang Z., Du H., Wang M., Wang J., Sun H., Kong L., Xu Q., Ma H., Sun Y. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharm. Sin. B. 2022;12:4011\u20134039. doi: 10.1016/j.apsb.2022.08.022.", "ArticleIdList": ["10.1016/j.apsb.2022.08.022", "PMC9643300", "36386472"]}, {"Citation": "Cheung M.K., Yue G.G.L., Chiu P.W.Y., Lau C.B.S. A Review of the Effects of Natural Compounds, Medicinal Plants, and Mushrooms on the Gut Microbiota in Colitis and Cancer. Front. Pharmacol. 2020;11:744. doi: 10.3389/fphar.2020.00744.", "ArticleIdList": ["10.3389/fphar.2020.00744", "PMC7243258", "32499711"]}, {"Citation": "Sevcikova A., Izoldova N., Stevurkova V., Kasperova B., Chovanec M., Ciernikova S., Mego M. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. Int. J. Mol. Sci. 2022;23:488. doi: 10.3390/ijms23010488.", "ArticleIdList": ["10.3390/ijms23010488", "PMC8745082", "35008915"]}, {"Citation": "Cheng W.Y., Wu C.Y., Yu J. The role of gut microbiota in cancer treatment: Friend or foe? Gut. 2020;69:1867\u20131876. doi: 10.1136/gutjnl-2020-321153.", "ArticleIdList": ["10.1136/gutjnl-2020-321153", "PMC7497589", "32759302"]}, {"Citation": "Zhang W., Huai Y., Miao Z., Qian A., Wang Y. Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery. Front. Pharmacol. 2019;10:743. doi: 10.3389/fphar.2019.00743.", "ArticleIdList": ["10.3389/fphar.2019.00743", "PMC6657703", "31379563"]}, {"Citation": "Huang C.F., Lin S.S., Liao P.H., Young S.C., Yang C.C. The immunopharmaceutical effects and mechanisms of herb medicine. Cell. Mol. Immunol. 2008;5:23\u201331. doi: 10.1038/cmi.2008.3.", "ArticleIdList": ["10.1038/cmi.2008.3", "PMC4652916", "18318991"]}, {"Citation": "Kingston D.G. Modern natural products drug discovery and its relevance to biodiversity conservation. J. Nat. Prod. 2011;74:496\u2013511. doi: 10.1021/np100550t.", "ArticleIdList": ["10.1021/np100550t", "PMC3061248", "21138324"]}, {"Citation": "Fabian K.P., Wolfson B., Hodge J.W. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Front. Oncol. 2021;11:728018. doi: 10.3389/fonc.2021.728018.", "ArticleIdList": ["10.3389/fonc.2021.728018", "PMC8419351", "34497771"]}, {"Citation": "Workenhe S.T., Pol J., Kroemer G. Tumor-intrinsic determinants of immunogenic cell death modalities. Oncoimmunology. 2021;10:1893466. doi: 10.1080/2162402X.2021.1893466.", "ArticleIdList": ["10.1080/2162402X.2021.1893466", "PMC7928029", "33717656"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "6", "Day": "9"}, {"Year": "2023", "Month": "7", "Day": "27"}, {"Year": "2023", "Month": "7", "Day": "31"}, {"Year": "2023", "Month": "8", "Day": "14", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "8", "Day": "12", "Hour": "10", "Minute": "43"}, {"Year": "2023", "Month": "8", "Day": "12", "Hour": "1", "Minute": "18"}, {"Year": "2023", "Month": "8", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["37570775", "PMC10421415", "10.3390/molecules28155804", "molecules28155804"]}}], "PubmedBookArticle": []}